Cellectis (NASDAQ:CLLS) Upgraded by BidaskClub to “Hold”

BidaskClub upgraded shares of Cellectis (NASDAQ:CLLS) from a sell rating to a hold rating in a research note released on Tuesday, BidAskClub reports.

A number of other brokerages have also weighed in on CLLS. BTIG Research initiated coverage on shares of Cellectis in a report on Friday, August 9th. They issued a buy rating and a $37.00 price objective for the company. ValuEngine upgraded shares of Cellectis from a sell rating to a hold rating in a report on Thursday, August 1st. Zacks Investment Research upgraded shares of Cellectis from a sell rating to a hold rating in a report on Monday, August 26th. Finally, Goldman Sachs Group set a $20.00 price objective on shares of Cellectis and gave the stock a hold rating in a report on Monday, August 12th. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $31.33.

NASDAQ:CLLS traded down $0.16 during mid-day trading on Tuesday, reaching $13.53. 88,900 shares of the company’s stock traded hands, compared to its average volume of 99,222. Cellectis has a 12-month low of $9.50 and a 12-month high of $22.66. The firm has a market capitalization of $564.16 million, a price-to-earnings ratio of -7.01 and a beta of 1.77. The company has a 50 day moving average price of $11.10 and a 200-day moving average price of $14.10. The company has a debt-to-equity ratio of 0.12, a current ratio of 7.99 and a quick ratio of 7.93.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Sumitomo Mitsui Trust Holdings Inc. raised its stake in Cellectis by 8.6% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,314,295 shares of the biotechnology company’s stock valued at $13,669,000 after buying an additional 104,276 shares during the last quarter. Nikko Asset Management Americas Inc. raised its stake in Cellectis by 7.3% during the 3rd quarter. Nikko Asset Management Americas Inc. now owns 1,314,295 shares of the biotechnology company’s stock valued at $13,669,000 after buying an additional 89,961 shares during the last quarter. ARK Investment Management LLC raised its stake in Cellectis by 18.1% during the 2nd quarter. ARK Investment Management LLC now owns 1,103,186 shares of the biotechnology company’s stock valued at $17,210,000 after buying an additional 169,110 shares during the last quarter. Morgan Stanley raised its stake in Cellectis by 56.6% during the 2nd quarter. Morgan Stanley now owns 494,775 shares of the biotechnology company’s stock valued at $7,719,000 after buying an additional 178,865 shares during the last quarter. Finally, Point72 Asset Management L.P. raised its stake in Cellectis by 66.9% during the 2nd quarter. Point72 Asset Management L.P. now owns 142,500 shares of the biotechnology company’s stock valued at $2,223,000 after buying an additional 57,100 shares during the last quarter. Institutional investors own 32.13% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.

Recommended Story: Most Active Stocks: Dollar Volume vs Share Volume

Analyst Recommendations for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.